Journal article
Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma
Abstract
Cytokine therapy with interferon-alpha and interleukin-2 has arguably been the standard treatment for patients with metastatic renal cell carcinoma for more than 20 years. In this paper, the current evidence for the use of cytokine therapy in this patient population is discussed, including the significant toxicity associated with these agents. A low overall response rate and a marginal survival advantage are observed with interferon-alpha and …
Authors
Kapoor AK; Hotte SJ
Journal
Canadian Urological Association Journal, Vol. 1, No. 2S, pp. s28–s33
Publisher
Canadian Urological Association Journal
Publication Date
6 2007
DOI
10.5489/cuaj.65
ISSN
1911-6470